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Abstract
Purpose: To determine the response and toxicity of docetaxel in recurrent osteosarcoma and related spindle cell tumours
of bone.
Patients and methods: Fourteen patients, 10 males and four females, were enrolled, median age 30.5 years (range, 17–46).
Diagnosis was: conventional osteosarcoma, 12 patients; periosteal osteosarcoma, one patient; and malignant fibrous
histiocytoma of bone, one patient. Initial chemotherapy had been with doxorubicin and cisplatin in 10 patients, and
multiagent regimens in four. Nine had been treated with second line chemotherapy before receiving docetaxel. Thirteen
patients had lung metastases and one intra-abdominal disease. Docetaxel 100mg/m
2 was given as a 1-h infusion every
3 weeks. Response was assessed every two cycles to a maximum of six.
Results: A total of 43 cycles were given, median of two per patient (range 1–6). Thirteen patients were evaluable for response.
A single partial remission was seen, for a response rate of 8%. Two patients had stable disease, and one patient a
mixed response. Forty cycles were evaluable for toxicity. The principle toxicity was haematological, with a median neutrophil
count of 0.9 (range 0–9.6). There were four episodes of neutropenic sepsis (10%). The only non-haematological toxicity
 grade 3 was stomatitis, occurring in just one patient. There were no toxic deaths.
Conclusion: Docetaxel at this dose and schedule is well tolerated, but is not associated with significant activity in patients
with relapsed osteosarcoma.
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Introduction
The outlook of patients with osteosarcoma has
dramatically improved over the last 25 years, so
that with the use of multi-agent chemotherapy and
surgery almost two-thirds of patients can expect to
be cured.
1–5
However, for patients who present with unres-
ectable or relapsed disease the outlook remains
poor.
6,7 For those with recurrent disease, surgery
is the most valuable treatment modality if cure
is to be achieved, but in some studies second
line chemotherapy has also been associated with
improved outcome.
7–9 In order to improve the
outlook for this group of patients, and achieve
further improvements in those with good prognosis
disease, new agents, active against this disease, are
needed.
Docetaxel is a semi-synthetic taxane, which in
common with other taxanes, promotes microtubule
assembly and inhibits disassembly thereby causing
cellular growth arrest.
10 Activity to docetaxel has
been identified in a wide range of tumours includ-
ing ovarian cancer,
11,12 breast cancer,
13–15 gastric
cancer,
16 non-small lung cancer
17 and limited activ-
ity in some sarcomas.
18–21 Sensitivity to docetaxel
has also been demonstrated in different osteosar-
coma cell lines,
22,23 although resistance was shown
to develop in one of these studies.
23
Synergistic activity of the combination of docetaxel
and cisplatin or carboplatin has been demonstrated
in various tumours.
24–26 As cisplatin is one of the
active agents in the treatment of osteosarcoma, the
identification of synergy with the taxoids could be
of potential significance, if response to docetaxel
in osteosarcoma was shown.
The aim of this study was to determine the activity
of docetaxel in patients with relapsed or refractory
osteosarcoma and related spindle cell sarcomas of
bone.
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Eligibility
Patients aged between 14 and 70 years with
relapsed or refractory histiologically proven osteo-
sarcoma or malignant fibrous histiocytoma of bone
(MFH-B) were eligible for this study. Eligibility
criteria included: WHO performance status  3 with
a life expectancy of greater than 8 weeks; measurable
or assessable disease; and adequate organ function,
defined as neutrophils  1.5 10
9/l; platelets  100 
10
9/l; serum creatinine  1.5 upper normal limit
(UNL); bilirubin  1 UNL; AST and/or ALT 
1.5 UNL; and alkaline phosphatase  2.5  UNL
(unless bone metastases present in the absence
of any liver disorder). Exclusion criteria included
co-existing illness precluding chemotherapy; preg-
nant or lactating women; symptomatic peripheral
neuropathy  grade 2; history of severe hypersen-
sitivity to polysorbate 80; and contraindications
to the use of steroids. The protocol was reviewed
and approved by a local ethics committee, and
written informed consent was obtained from patients
and/or parents where appropriate.
Pre-treatment evaluation
At study entry patients had a complete history and
physical examination, including performance status,
assessment of residual toxicity and clinical tumour
measurements. Blood tests including full blood
count, chemistry, baseline alkaline phosphatase and
lactate dehydrogenase were also performed. Imaging
included chest X-ray and computed tomography
(CT) of the chest, isotopic bone scan, and plain
X-rays or magnetic resonance imaging (MRI) of the
primary tumour where appropriate.
Treatment
Docetaxel 100mg/m
2 was given on an outpatient
basis, as a 1-h intravenous infusion every 21 days,
for a maximum of six cycles. Dexamethasone, 8mg
twice daily, was given as a pre-medication, starting
the day before the infusion, and continued for 5 days
in total.
Patients were clinically reassessed every 3 weeks,
including clinical history since previous infusion
and assessment of toxicity. Full blood count and
chemistry was undertaken before the start of each
cycle, and full blood tests also performed at days 8
and 15 of each cycle. In the event of continuing
toxicity, treatment was delayed for a maximum of
2 weeks to allow for haematological recovery of
neutrophils to  1.0 or platelets  75, or of non-
haematological toxicity to grade 1 or below. In the
event of prolonged neutropenia (neutrophils <0.5
for more than 7 days) or neutropenic sepsis, the dose
of subsequent cycles was reduced by 25%. In the
event of grade 4 neutropenia of  7 days without
neutropenic sepsis, granulocyte-colony stimulating
factor (G-CSF) was considered.
Evaluation of response
Response to docetaxel was assessed after every
two cycles of chemotherapy according to the WHO
criteria for clinical response.
27 Complete response
(CR) was defined as the total disappearance if all
lesions determined by two observations, not less
than 4 weeks apart; partial response (PR) was the
decrease in the sum of at least 50% in the sum of
the products of the largest perpendicular dimensions
of all measurable lesions; a minor response (mR)
indicated the decrease of  25%, but <50% in the
sum of all measurable lesions; and progressive
disease (PD) indicated an increase of  25% in the
sum of the largest perpendicular dimensions of all
measurable lesions or the appearance of new disease
at any site. Stable disease (SD) was less than 25%
decrease or increase in all measurable lesions, and
the absence of any new disease.
Toxicity was graded according to the National
Cancer Institute – Common Toxicity Criteria
(NCI-CTC), version 2.0.
28
Results
The patient characteristics are shown in Table 1.
A total of 14 patients, 10 males and four females
were entered. The median age at study entry was
30.5 years (range 17–46). Diagnosis was: conven-
tional osteosarcoma in 12 patients; periosteal
osteosarcoma in one patient; and MFH-B in one.
Eleven patients (79%) had presented with locali-
sed extremity tumours at diagnosis, two with
extremity tumours with lung metastases, and one
patient with a localised pelvic tumour. First line
chemotherapy had been with doxorubicin and cis-
platin in 10 patients, and multiagent regimens in
the remaining four. All had undergone surgery to the
primary, three with adjuvant radiotherapy.
The timing of treatment with docetaxel was
first recurrence in four patients, and second or sub-
sequent recurrence in 10. Nine patients had received
prior chemotherapy for relapsed disease, seven with
surgery. One further patient had undergone surgery
and adjuvant radiotherapy for a local recurrence 7
months prior to treatment with docetaxel for a meta-
static recurrence in the lung. The median number
of previous chemotherapy regimens received was 2
(range, 1–3) and the median number of previous
chemotherapy agents received was 4 (range, 2–9).
Site of disease at the start of treatment with
docetaxel was: lung in eight patients, combined
local and lung metastases in two, lung and bone in
two, lung and subcutaneous metastases in one,
and intra-abdominal disease in one. The median
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Patient Diagnosis
Age
(years) Primary
First line
chemotherapy Local therapy
Prior chemotherapy
for relapse
Timing of
docetaxel
Site of
disease
Docetaxel
No. of
cycles
Best
response
1 OS 46 Distal femur DoxþCisp 6 EPR None 1
st Recurrence Lung 2 PD
2 OS 30 Distal femur Multi agent EPR IfoþEto 6> 2
nd Recurrence Lung & Bone 2 PD
3 MFH-B 44 Proximal humerus DoxþCisp 5 EPR IfoþEto 6;
HD-Mtx
>2
nd Recurrence Lung 2 PD
4 OS 17 Proximal tibia DoxþCisp 5 EPR None 2
nd Recurrence Local & Lung 6 SD
5 OS 19 Proximal tibia DoxþCisp 6 EPRþRT HD-Mtx;
IfoþEto 5
>2
nd Recurrence Lung 2 PD
6 OS 33 Pelvis Dox,CispþIfo 6 Hemi-
pelvectomyþRT
None 1
st Recurrence Hypochondrium 1 PD
7 OS 23 Proximal tibia DoxþCisp 4 EPR IfoþEto 2> 2
nd Recurrence Local & Lung 1 (SD)
a
8 OS 42 Proximal tibia DoxþCisp 3 Amputation IfoþEto 6> 2
nd Recurrence Lung 2 PD
HD-Mtx 1;
DoxþCarb 2
9 Per-OS 33 Distal femur DoxþCisp 4 EPR DoxþCisp 2;
IfoþEto 6
>2
nd Recurrence Lung & Bone 4 PD
10 OS 33 Proximal humerus DoxþCisp 6 EPRþRT None 1
st Recurrence Lung 2 PD
11 OS 21 Proximal humerus DoxþCisp 4;
Ifo 2
EPR None 1
st Recurrence Lung 6 SD
12 OS 17 Proximal tibia DoxþCisp 6 Amputation IfoþEto 4;
HD-Mtx 3
>2
nd Recurrence Lung 6 PR
13 OS 31 Proximal humerus DoxþCisp 6 EPR IfoþEto 6> 2
nd Recurrence Lungþ
Subcutaneous
nodule
5P D
(Mixed)
14 OS 19 Proximal tibia DoxþCisp 6 EPR IfoþEto 6;
HD-Mtx 6
>2
nd Recurrence Lung 2 PD
aNot formally evaluable for response as changed to carboplatin following anaphylactic reaction to docetaxel
Abbreviations: OS, conventional osteosarcoma; Per-OS, periosteal osteosarcoma; MFH-B, malignant fibrous histiocytoma of bone;
Dox, doxorubicin; Cisp, cisplatin; Carb, carboplatin; Ifo, ifosfamide; HD-Mtx, methotrexate 12g/m
2; Eto, etoposide;
EPR, endo-prosthetic replacement; RT, radiotherapy; PD, progressive disease; SD, stable disease; PR, partial response.
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3treatment-free interval before the start of docetaxel
was 44 weeks (range, 14–454).
A total of 43 cycles were given, with a median of
two per patient (range, 1–6). Dose reductions were
required in eight of the 43 cycles (19%), affecting
five patients. Dose reductions were given for neutro-
penic sepsis in four patients, and cumulative toxicity
in one. Later in the series, two heavily pre-treated
patients received prophylactic G-CSF from the start
of treatment. Cycles were given at a median of every
21 days, with only one cycle being delayed to coin-
cide with a clinic visit.
Forty cycles were assessable for toxicity (Table 2).
The principle toxicity was haematological, with a
median neutrophil count of 0.9 (range, 0–9.6). Four
cycles (10%) were complicated by neutropenic
sepsis. Only one patient experienced a non-haema-
tological toxicity of greater than grade 2, developing
a grade 3 stomatitis after two consecutive cycles
of chemotherapy. However, one patient experienced
an immediate anaphylactic reaction (grade 2) to his
second cycle of docetaxel, which resolved sponta-
neously when the infusion was stopped. As there had
been no response observed after the first cycle of
docetaxel, no further docetaxel was given and the
patient elected to receive single-agent carboplatin.
Other grade 1–2 non-haematological toxicities
included: stomatitis in eight patients; lethargy in
eight patients; diarrhoea in six patients; constipation
in four patients; myalgia in three patients; nausea in
three patients; neuropathy in two patients; and vomit-
ing, arthralgia, and headache in one patient each.
Response
Thirteen patients were evaluable for response.
The remaining patient switched from docetaxel to
carboplatin after an anaphylactic reaction to
docetaxel, but had stable disease after the first
cycle. Of the 13 patients who remained evaluable
for response, only one PR was observed, lasting 9
weeks, for an overall response rate of 8%. Two
patients had stable disease for durations of 15 and
33 weeks, respectively. One further patient had a
mixed response with a greater than 50% reduction
of a cutaneous metastasis and reduction in pre-
existing lung metastases, but developed synchro-
nous metastases during treatment, giving an overall
response of PD. All 14 patients have subsequently
died of progressive disease, at a median of 8 months
from the start of docetaxel chemotherapy (range,
1–20 months).
Discussion
The prognosis of patients with localised extremity
osteosarcoma has improved dramatically with the
use of multi-agent chemotherapy in addition to
surgery over the past few decades. However, for
those with unresectable or recurrent disease the
prognosis remains poor. The response rate of just
8% to docetaxel in this study is therefore dis-
appointing, suggesting little activity at this dose and
schedule in patients who relapse with osteosarcoma
after conventional chemotherapy. Furthermore the
only response seen was of a very short duration
(9 weeks).
There are few published data examining the
efficacy of docetaxel in patients with osteosarcoma.
In a phase I dose-escalating study of docetaxel
55–150mg/m
2 in paediatric solid tumours, no
responses were observed in 11 patients with osteo-
sarcoma.
29 Similarly, in a subsequent dose-escalating
study of docetaxel 150–235mg/m
2 with filgrastim
Table 2. Treatment-related toxicity
Cycles with toxicity No. (%)
Patients with toxicity
(all grades) No. (%) Grade 1 2 3 4
Toxicity
White blood count 11 (28) 12 (30) 3 (8) 5 (13) 13 (93)
Neutropenia 4 (10) 3 (8) 11 (28) 11 (28) 13 (93)
Anaemia 29 (73) 7 (18) 2 (5) 13 (93)
Thrombocytopenia 1 (3) 2 (5) 3 (21)
Anaphylaxis 1 (3) 1 (7)
Arthralgia 1 (3) 1 (3) 1 (7)
Lethargy 5 (13) 4 (10) 8 (57)
Myalgia 3 (8) 3 (21)
Diarrhoea 6 (15) 1 (3) 6 (43)
Nausea 4 (10) 2 (5) 3 (21)
Vomiting 1 (3) 1 (7)
Stomatitis 10 (25) 8 (20) 2 (5) 9 (64)
Infection 1(3) 4 (10) 5 (36)
Constipation 3 (8) 3 (8) 4 (29)
Headache 1 (3) 1 (7)
Neuropathy 3 (8) 1 (3) 2 (14)
Number of evaluable cycles¼40; total number of patients¼14.
74 A. McTiernan & J.S. Whelansupport in paediatric patients, no responses were
seen in a further nine patients with osteosarcoma.
30
Another taxane which has been studied in osteo-
sarcoma is paclitaxel. Patel et al.
31 treated 15 patients
with osteosarcoma and its variants (i.e., including
three patients with MFH-B and two with dediffer-
entiated chondrosarcoma) with paclitaxel 175mg/m
2.
No responses, other than one mixed response, were
observed. Four paediatric patients with osteosar-
coma included in two separate phase I studies of
paclitaxel in paediatric solid tumours also failed to
respond to paclitaxel chemotherapy.
32,33
Although many of the patients in this study had
been heavily pre-treated, the drug was well tolerated
with only four episodes of neutropenic sepsis seen.
All other toxicities were easily managed in the out-
patient setting.
In conclusion, docetaxel at 100mg/m
2 as a 1-h
infusion is well tolerated, but is not effective in
relapsed or refractory osteosarcoma. Similar results
seen in other small studies suggest that taxanes
have no role to play in the treatment of osteosar-
coma. Further combination studies with platinum
compounds do not therefore appear to be warranted.
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